Figure 2.
Analysis of progression-free survival for patients with favourable-risk disease. (A) Network diagram: the size of every treatment node corresponds to the number of randomly assigned patients. The width of the lines is proportional to the number of trials. (B) Forest plot, with sunitinib as the comparator. (C) Ranking of treatments. Rankograms were drawn according to distribution of the ranking probabilities. Ranking indicates the probability to be the best treatment, the second best, the third best, and so on, in terms of progression-free survival (PFS), among the 13 treatments. Numbers in parentheses indicate 95% credible intervals. AVE_AXI, avelumab plus axitinib; AXI, axitinib; BEV_IFN, bevacizumab plus interferon; EVE, everolimus; IFN, interferon; NIV_IPI, nivolumab plus ipilimumab; PAZ, pazopanib; PEM_AXI, pembrolizumab plus axitinib; PLA, placebo; SOR, sorafenib; SUN, sunitinib; TEM_BEV, temsirolimus plus bevacizumab; TIV, tivozanib.